Plant Name: Juniperus ashei
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; | |
| TDP1; CTDSP1; HKDC1; HSD17B1; AKR1B1; HSD17B2; GFER; HSD17B10; AKR1B10; NOX4; ALOX15; ALDH1A1; USP2; | |
| DAPK1; FLT3; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA3; CA5B; CA5A; CA4; CA6; | |
| AR; | |
| NR1H4; | |
| ESR2; | |
| ESRRA; | |
| ALOX5; TYR; XDH; | |
| CASP1; CASP7; | |
| AHR; HIF1A; TP53; | |
| ABCG2; ABCC1; | |
| LMNA; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | HKDC1 | Putative hexokinase HKDC1 | Q2TB90 | CHEMBL1741200 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.909E-11 | 3.464E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.077E-11 | 3.478E-08 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, GFER, HSD17B1, HSD17B10, HSD17B2, NOX4, TYR, XDH |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.050E-10 | 6.934E-07 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, ESRRA, NR1H4, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.289E-09 | 1.404E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.510E-09 | 1.566E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.295E-09 | 4.435E-06 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, XDH |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.373E-07 | 7.474E-05 | AR, CA2, CA9, CASP1, CYP1A1, CYP1A2, ESRRA, FLT3, HSD17B2, NR1H4, TP53, TYR |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.344E-07 | 7.474E-05 | AHR, AR, ESR2, ESRRA, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:1901700; response to oxygen-containing compound | 2.734E-07 | 1.294E-04 | AKR1B1, AR, CA3, CA9, CASP1, CYP1A1, CYP1A2, CYP1B1, DAPK1, ESRRA, HSD17B2, NOX4, NR1H4, TP53, TYR |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.865E-07 | 1.327E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 5.500E-07 | 2.444E-04 | ABCC1, AKR1B1, AKR1B10, ALDH1A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, HKDC1 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 7.002E-07 | 3.049E-04 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, CYP1A1, CYP1B1, HIF1A, NR1H4, TYR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 7.353E-07 | 3.139E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.291E-06 | 8.455E-04 | AR, ESR2, ESRRA, HSD17B1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.778E-27 | 1.911E-22 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.119E-06 | 1.132E-03 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 4.235E-06 | 1.487E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.382E-05 | 4.121E-03 | AR, ESR2, ESRRA, NR1H4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.811E-05 | 5.056E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.811E-05 | 5.056E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.811E-05 | 5.056E-03 | GPBAR1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0009719; response to endogenous stimulus | 2.298E-05 | 6.333E-03 | AKR1B1, AR, CA2, CA9, CASP7, CYP1A2, ESRRA, FLT3, NOX4, NR1H4, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.463E-05 | 6.621E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.463E-05 | 6.621E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0008210; estrogen metabolic process | 2.810E-05 | 7.284E-03 | CYP1B1, HSD17B1, HSD17B2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.617E-05 | 8.560E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.617E-05 | 8.560E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 3.617E-05 | 8.560E-03 | ALDH1A1, AR |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 4.198E-05 | 9.725E-03 | CASP1, CYP1A1, HIF1A, LMNA, NOX4, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.687E-20 | 5.103E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.983E-19 | 3.476E-15 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.410E-26 | 5.248E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.097E-07 | 4.060E-06 | ALOX15; AKR1B1; CYP2C19; TYR; HSD17B10; CYP2C9; AKR1B10; HSD17B1; ALOX5; HKDC1; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; XDH |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.256E-07 | 4.060E-06 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.677E-07 | 6.491E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.636E-07 | 1.287E-05 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.527E-06 | 2.468E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.471E-05 | 2.038E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.003E-05 | 2.159E-04 | FLT3; HKDC1; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.775E-05 | 2.153E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.814E-05 | 2.730E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.500E-04 | 9.697E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.204E-04 | 8.344E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.033E-05 | 4.438E-04 | AKR1B10; HKDC1; AKR1B1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.082E-04 | 3.687E-03 | CYP2C9; CYP1A2; CYP2C19 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.553E-03 | 1.303E-02 | AR; FLT3; DAPK1; HIF1A; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.612E-04 | 3.773E-03 | CA2; NR1H4; ABCG2 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 6.128E-05 | 4.572E-04 | AKR1B10; HKDC1; AKR1B1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.613E-03 | 2.034E-02 | CASP7; LMNA; TP53 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 7.634E-03 | 2.882E-02 | CASP7; MAPT; HSD17B10 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.357E-03 | 2.013E-02 | DAPK1; TP53 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 8.846E-03 | 3.178E-02 | AKR1B10; AKR1B1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 7.724E-03 | 2.882E-02 | CASP7; CASP1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 6.672E-03 | 2.697E-02 | CASP1; TP53 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 3.373E-03 | 1.636E-02 | AKR1B10; AKR1B1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.400E-02 | 4.683E-02 | CASP7; CASP1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 5.004E-03 | 2.110E-02 | ABCC1; ABCG2 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.382E-03 | 7.446E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.614E-05 | 4.538E-04 | CYP1A2; XDH |
| hsa00524 | Butirosin and neomycin biosynthesis_Homo sapiens_hsa00524 | 1.194E-02 | 4.138E-02 | HKDC1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | GPBAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| C00-D49: Neoplasms | Melanoma | C43 | TYR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| NA: NA | HIV infections | NA | AHR |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; ABCC1; ESRRA |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ESRRA |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; CA1; FLT3; FLT3; CA9 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; CASP1; AKR1B1; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |